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Targeting CCR2 and CCR5 receptors is considered as promising concept for the development of novel 
antiinflammatory drugs. Herein, we present the development of the first probe-dependent positive 
allosteric modulator (PAM) of CCR5 receptors with a 2-benzazepine scaffold. Compound 14 (2-
isobutyl-N-({[N-methyl-N-(tetrahydro-2H-pyran-4-yl)amino]methyl}phenyl)-1-oxo-2,3-dihydro-1H-2-
benzazepine-4-carboxamide) activates the CCR5 receptor in a CCL4-dependent manner, but does not 
compete with [3H]TAK-779 binding at the CCR5. Furthermore, introduction of a p-tolyl moiety at 7-
position of the 2-benzazepine scaffold turns the CCR5 PAM 14 into the selective CCR2 receptor 
antagonist 26b. The structure affinity and activity relationships presented here offer new insights into 
ligand recognition by CCR2 and CCR5 receptors. 
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1. Introduction 
Since the first purification and description of the chemoattractant cytokine secreted platelet factor 4 
(PF4/CXCL4) in 19771 more than 50 human chemokines have been discovered.2 Their effects are 
mediated by 19 G-protein-coupled chemokine receptors. The chemokine receptors CCR2 and CCR5 
share 72% sequence identity (82% identity in their active sites).3 Both receptors play a crucial role in 
trafficking of immune cells such as macrophages and monocytes, relevant for the development and 
progression of immunologic and cardiovascular diseases.4 The CCR2 receptor is abundantly expressed 
on blood monocytes and regulates their migration from the bone marrow into inflamed tissue, whereas 
the CCR5 receptor is expressed on macrophages, T-lymphocytes, and natural killer cells..5-7 CCR2 and 
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CCR5 receptors are expressed on different cells, but in a complementary manner. Therefore, dual as 
well as selective targeting of CCR2 and CCR5 receptors appears to have great potential in the 
development of novel concepts for the therapy of inflammatory diseases (e.g. atherosclerosis).5 
 
The benzo[7]annulene TAK-779 (1) represents one of the first potent non-peptide CCR5 receptor 
antagonists (IC50 = 1.4 nM, Figure 1). TAK-779 does not only interact with the CCR5 receptor, but also 
with the CCR2 receptor, although its CCR2 affinity is about 20-fold lower (IC50 = 27 nM) compared to 
its CCR5 affinity.8 However, the quaternary ammonium group of TAK-779 leads to very low oral 
bioavailability. Therefore, very recently we have reported a large structure affinity relationship study 
with TAK-779 analogs containing a tertiary amine instead of the quaternary ammonium group. 
Depending on the substitution pattern, potent CCR2 selective and dual CCR2 and CCR5 targeting 






































In addition to TAK-779, the benzazocine TAK-652 (2) served as lead compound in this project (Figure 
1). TAK-652 shows high and similar affinities towards CCR5 (IC50 = 3.1 nM) and CCR2 receptors (IC50 
= 5.9 nM), but does not contain a quaternary ammonium group, which had been replaced by a polar 
sulfoxide.12 Structure affinity relationship (SAR) studies performed by Takeda laboratories have shown 
that reduction of the ring from a benzazocine to a benzazepine did not result in considerable loss of 
CCR5 affinity. The introduction of an isobutyl side chain onto the benzazocine ring increased CCR5 
binding affinity.12  
 
Thus, we envisaged to combine the structures of TAK-779 and TAK-652 in 2-benzazepinones 3. The 
dihydro-2-benzazepin-1-one system of 3 contains a benzannulated seven-membered ring as TAK-779 
and an N-heterocycle bearing an isobutyl moiety as TAK-652. The basicity of the amino group in TAK-
652 (2) is rather low, due to its position at the phenyl ring and due to its conjugation with the amide 
group at 5-position (phenylogous / vinylogous urea). In the dihydro-2-benzazepin-1-one system 3 the 
basicity of the N-heterocycle is also negligible (lactam). The position of the lipophilic isobutyl moiety 
(red) is shifted from 1-position in TAK-652 (2) to 2-position in 3. The selection of substituents X and R 
was inspired by the substituents of the lead compounds 1 and 2 and our previous SAR studies.9-11 The 
interaction of the final compounds with CCR2 and CCR5 receptors was evaluated in various 
biochemical assays. 
 
2. Results and discussion 
2.1. Synthesis 
The synthesis of the central building block 11 started with a Michael addition of isobutylamine (5) at 
methyl acrylate (4) yielding the aminopropanoate 6, which was purified as HCl salt (Scheme 1). Amine 
6 was acylated with commercially available 2-(methoxycarbonyl)benzoic acid (monomethyl phthalate, 
5 
 
7), which was first converted into its acid chloride using SOCl2. Treatment of the resulting diester 8 with 
NaH in boiling THF induced the Dieckmann cyclization to produce the cyclic β-ketoester 9. According 































































































Scheme 1: Synthesis of compounds 14 and 16. Reagents and reaction conditions: (a) 1. NaOCH3, 
H3COH, rt, 2 h; 2. HCl/Et2O, 89%. (b) Monomethyl phthalate (7), SOCl2, pyridine; then addition of 
6·HCl, pyridine, CH2Cl2, rt, 4 h, 64%. (c) NaH, THF, reflux, 3 h, 58%. (d) NaBH4, H3COH, 0 °C, 1 h, 
58%. (e) H3CSO2Cl, NEt3, DBU, CH2Cl2, rt, 12 h, 76%. (f) 5 M NaOH, H3COH, reflux, 40 min, 100%. 




Reduction of the enol ester 9 with NaBH4 in H3COH afforded two diastereomeric β-hydroxy esters 10. 
Since in the next step both diastereomers of 10 form the same α,β-unsaturated ester 11, the 
diastereomeric β-hydroxy esters 10 were not separated. Elimination of H2O was performed upon 
treatment of β-hydroxy esters 10 with methanesulfonyl chloride in the presence of NEt3. Subsequent 
addition of DBU induced the β-elimination of the intermediate methanesulfonate to give the α,β-
unsaturated ester 11 in 76% yield. Saponification of methyl ester 11 with NaOH provided the acid 12 in 
almost quantitative yield.  
 
The acid 12 was used to prepare secondary amides 14 and 16, which have similar structures as the lead 
compounds 1 and 2. For the amide coupling the uronium salt O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluorophosphate (HATU) was used. Whereas coupling of acid 12 with the 
primary amine 13 provided the secondary amide 14 in 48% yield, the corresponding coupling with 
sulfathiazole (15) gave only 8% of secondary amide 16. 
 
In the BRET-based cAMP assay, TAK-779-derived secondary amide 14 showed a CCL4-dependent 
positive allosteric modulation (PAM) of CCR5 receptor (see part 3, Biological activity), whereas the 
sulfonamide derivative 16 was inactive, indicating the requirement of a basic benzylamine moiety for 
CCR5 receptor binding.  This promising result stimulated further exploration of the substitution pattern 
of compound 14. At first, a bromine atom should be introduced into the benzene moiety of the 2-
benzazepine ring of the key compound 11, since bromoarenes could be used for the introduction of a 
broad variety of diverse substituents by Pd-catalyzed cross-coupling reactions. Unfortunately, all 
attempts to brominate 11 using Br2 or NBS under different reaction conditions led to loss of the double 





Therefore, it was planned to change the synthetic strategy and introduce the Br-atom at a very early 
stage of the synthesis.  For this purpose, phthalic anhydride (17) was treated with an aqueous solution of 
NaOH and Br2 which provided 4-bromophthalic acid (18)13 in 95% yield (Scheme 2). Treatment of 
diacid 18 with methanol in the presence of TMSCl provided a 1:1 mixture of regioisomeric monomethyl 
esters 19a and 19b in 94% yield. The further synthetic route to obtain esters 23 is very similar to the 
synthesis of ester 11. Activation of the mono acids 19a,b with SOCl2 and subsequent reaction of the acid 
chlorides with aminopropanoate 6 led to the amides 20, which underwent Dieckmann condensation to 
afford the enol esters 21a,b. NaBH4 reduction of 21a,b provided the β-hydroxyesters 22a,b, which 
reacted with mesyl chloride and DBU to yield the α,β-unsaturated esters 23a,b. In the next step the p-
tolyl moiety of the lead compound TAK-779 (1) should be introduced. Suzuki-Miyaura cross-coupling 
of the regioisomeric bromo derivatives 23a,b with 4-methylbenzeneboronic acid and PdCl2(dppf) as 
catalyst provided the regioisomeric p-tolyl derivatives 24a,b. Saponification of the esters 24a,b with 
























24a,b: R = CH3
 





























































Scheme 2: Synthesis of 7- and 8-(p-tolyl)-2-benzazepine-4-carboxamides 26a,b. Reagents and reaction 
conditions: (a) Br2, NaOH, H2O, reflux, 72 h, 95%. (b) TMSCl, H3COH, rt, 12 h, 94%. (c) 1. SOCl2, 
pyridine; 2. 6·HCl, pyridine, CH2Cl2, rt, 4 h, 64%. (d) NaH, THF, reflux, 3 h, 21a: 36%, 21b: 38%. (e) 
NaBH4, H3COH, 0 °C, 1 h, 22a: 58%, 22b: 45%. (f) H3CSO2Cl, NEt3, DBU, CH2Cl2, rt, 12 h, 23a: 74%, 
23b: 84%. (g) 4-Methylbenzeneboronic acid, PdCl2(dppf) (5 mol%), KOAc, DME, reflux, 12 h, 24a: 
50%, 24b: 58%. (h) 5 M NaOH, H3COH, reflux, 30 min, 97%. (i) 13, HATU, NEt3, THF, rt, 12 h, 26a: 
39%, 26b: 34%. 
 
The separation of the regioisomers a and b was performed at various stages at the synthesis. Separation 
at the very early stage of enol esters 21 and performing the synthesis with pure regioisomers 21a and 
21b gave clear spectra of all intermediates. An X-ray crystal structure of the 7-bromo derivative 21b 
proved the existence of the β-ketoester in the enol tautomer and the position of the Br-atom.14 
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Separation of the intermediate α,β-unsaturated esters 23a and 23b gave higher yields than the early 
separation of 21a and 21b. However, separation of the final p-tolyl derivatives 26a and 26b turned out 
to be the most efficient strategy, since the corresponding transformations and purifications had to be 
performed only once for the mixture of regioisomers, respectively. However, preparative HPLC had to 



































CH3O30a: R = H 
31a: R = Ac(e)
32a: R = H 





27a: R = CH3 
28a: R = H(b)
27c: R = CH3 


















Scheme 3: Synthesis of NO2 derivatives 29 and acetamide 34a. Reagents and reaction conditions: 
(a) HNO3 (100%), H2SO4 (95 – 97%), CH3NO2, rt, 2 h, 83%. (b) 5M NaOH, H3COH, reflux, 97%.  (c) 
13, HATU, NEt3, THF, rt, 12 h, 29a: 9%, 29c: 14%. (d) Fe, conc. HCl, EtOH, reflux, 2 h, 75%. (e) 
Ac2O, NEt3, CH2Cl2, 6 h, rt, 59%. (f) NaOH, H3COH, 10 min, rt. (g) Ac2O, NEt3, CH2Cl2, 6 h, rt, 69%. 
(h) 13, HATU, NEt3, THF, rt, 12 h, 47%. 
 
In addition to the p-tolyl moiety, the introduction of electron withdrawing NO2 group was envisaged, 
which could be converted into various other functional groups, subsequently. For this purpose, the naked 
α,β-unsaturated ester 11 was reacted with HNO3/H2SO4 to obtain a mixture of regioisomeric 8-NO2- and 
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6-NO2-2-benzazepines 27a and 27c in the ratio 7:3 in 97% yield (Scheme 3). After chromatographic 
separation of the regioisomeric esters 27a and 27c, saponification with NaOH led to the acids 28a and 
28c, which were coupled with the amine 13 to afford the final amides 29a and 29c. 
 
The main regioisomer 27a was reduced with Fe in the presence of HCl to provide the primary amine 
30a, which was acylated with Ac2O to give the acetamide 31a (Scheme 3). In the next step, the ester 31a 
was treated with NaOH. Unexpectedly, not only the ester moiety but also the acetamide group was 
hydrolyzed to produce the amino acid 32a. Therefore, the amino moiety was acetylated once more with 
Ac2O, before the final HATU-coupling of the acid 33a with amine 13 was performed to produce the 





































Scheme 4: Synthesis of sulfonamide 38a: Reagents and reaction conditions: (a) Fe, conc. HCl, EtOH, 
reflux, 2 h, 74%. (b) CH3SO2Cl (1 equiv.), NEt3, CH2Cl2, 3 d, then 4 x 0.3 equiv. CH3SO2Cl and NEt3 
every 6 h, rt, 91%. (c) NaOH, H3COH, 20 min, rt, 43%. (d) LiOH (4 equiv.), H3COH, 3 h rt, 1 h 50 °C, 
53%.  (e) 13, HATU, NEt3, THF, rt, 12 h, 20%. 
 
Reduction of the regioisomers NO2-derivatives 27a,c with Fe and conc. HCl provided a mixture of 
regioisomeric primary amines 30a,c, which was treated with methanesulfonyl chloride in the presence of 
triethylamine. Although only one equivalent of methanesulfonyl chloride was added, considerable 
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amounts of disulfonamides 35a,c were formed. Therefore, an excess of methanesulfonyl chloride was 
used to obtain the disulfonamides 35a,c in 91% yield. Subsequent hydrolysis of the disulfonamides 
35a,c with NaOH in methanol produced the monosulfonamides 36a,c. Finally, the ester moiety of 36a,c 
was hydrolyzed with LiOH. Chromatographic purification of the resulting acids provided the main 
regioisomer 37a in 53% yield, which was coupled with the amine 13 to afford the amide 38a in 20% 
yield (Scheme 4). 
 
2.2. Biological activity 
The interaction of sulfathiazole coupled amide 16 as well as 2-benzazepine-4-carboxamides 14, 26, 29, 
34, and 38 bearing different substituents in 8- (a-series), 7- (b-series) and 6-position (c-series) with 
CCR2 and CCR5 receptors was tested in various CCR2 and CCR5 assays. 
 
In the first assay, the test compounds competed with the radioligand [3H]INCB3344 for CCR2 receptor 
binding on membrane preparations from U2OS cells stably expressing CCR2. With exception of the 7-
p-tolyl derivative 26b, the test compounds did not reduce the specific binding of the radioligand 
[3H]INCB3344 to a large extent at a concentration of 1 µM indicating rather low CCR2 affinity (Table 
1). Only the 7-p-tolyl derivative 26b displayed a moderate CCR2 affinity with an IC50 value of 387 nM. 
 
In addition to binding, the antagonistic activity of the test compounds at the CCR2 receptor was 
determined in a Ca2+ flux assay employing the Chem-1 cell line stably transfected with the human 
CCR2b receptor. Influx of Ca2+ ions was induced by recombinant human CCL2 (MCP-1). The inhibition 
of this Ca2+ influx by the test compounds was recorded. Table 1 shows that only the p-tolyl derivatives 
26 were able to inhibit the Ca2+ influx. Whereas the 8-p-tolyl derivative 26a revealed only very low 
inhibition, a significant inhibition was observed for the regioisomer 26b. This result is explained by the 
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structural relationship of 26b and the lead compound TAK-779. However, the IC50 value of 140 nM is 
considerably higher than the IC50 value of TAK-779. The inhibition of the Ca2+ flux induced by the 7-p-
tolyl derivative 26b correlates nicely with its moderate CCR2 binding affinity. 
 
































[%] inhibition at a test compound concentration of 1 μM (n = 3). n.d. not determined. 
[a] Displacement of the radioligand [3H]INCB3344 at a concentration of 1 µM of the test 
compound (n = 3). 
[b]  Inhibition of Ca2+ mobilization after activation by 5 nM MCP-1 (n = 3). 
 [c] Displacement of the radioligand [3H]TAK-779 at a concentration of 1 µM of the test 













14 H 18% n.d. 0% 2470 
16 H 18% n.d. 0% > 10 
26a 8-p-tolyl 0% 3000 0% > 10 
26b 7-p-tolyl 387 140 0% > 10 
29a 8-NO2 9% n.d. 0% > 10 
29c 6-NO2 6% n.d. 0% > 10 
34a 8-NHAc 15% n.d. 0% > 10 
38a 8-NHSO2CH3 18% n.d.         0% > 10 
TAK-779 - 50 0.95 2  7  
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compound (n = 3). 
[d] Stimulation of cAMP production after inhibition with 0.2 nM CCL4 (n = 3). 
 
For investigation of the interaction of the test compounds with CCR5 receptors, a binding assay was 
performed at first. In this assay the radioligand [3H]TAK-779 was used as competitor and commercially 
available membrane preparations containing high amounts of CCR5 receptors were employed as source 
of receptors. At a concentration of 1 µM the test compounds could not displace the specific radioligand 
binding (Table 1). In particular, the low CCR5 interaction of the p-tolyl derivative 26b was unexpected, 
as this compound is structurally very similar to the lead compound TAK-779. To address the surprising 
lack of CCR5 affinity of compound 26b, the central core structures of 26b (B) and TAK-779 (A) were 
compared via flexible alignment. In Figure 2, part I the superposition of the core structures demonstrates 
different angles within the 7-membered rings of TAK-779 (1) and 2-benzazepinone 26b. The different 
arrangement of the 7-membered ring of 26b compared to TAK-779 might explain the reduced or 
eliminated CCR5 affinity of 26b. Obviously, the CCR5 receptor does not tolerate the introduction of the 
N-isobutyl substituted amide moiety within the seven-membered part of the ring system. On the other 
hand, an alignment of the core structures of 26b (B) and TAK-652 (C) (Figure 2, part II) reveals a very 























Figure 2: I) Alignment of central core structures of TAK-779 (A, blue) with 7-p-tolyl derivative 26b (B, 
pink). II) Alignment of central core structures of TAK-652 (C, orange) with 7-p-tolyl derivative 26b (B, 
pink). 
 
To assess the effect of compounds on the CCL4 or CCL5-induced Gi protein-dependent signaling of 
CCR5, we monitored the changes in cAMP levels by use of the bioluminescence resonance energy 
transfer- (BRET-) based cAMP sensor CAMYEL. This biosensor is comprised of a catalytically inactive 
Epac1 that is fused to Citrine at its N-terminus and to Renilla reniformis luciferase (Rluc) at the C-
terminus.15 For these experiments, HEK293T cells were transiently transfected with the human CCR5 
receptor and the CAMYEL biosensor. The accumulation of cAMP was induced by forskolin. TAK-779 
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Figure 3: The BRET-based cAMP assay for compounds 14 and TAK-779 (1) with CCL4 at the CCR5 
receptor.  
 
In the cAMP assay only the unsubstituted 2-benzazepinone 14 displayed remarkable biological effects. 
This compound showed clear probe-dependence at the CCR5 receptor. Although that compound 14 
itself had no intrinsic agonist activity (Figure 3),  it behaved as positive allosteric modulator (PAM) 
when CCL4 was used to activate the CCR5 receptor (IC50 = 2.47 μM, Table 1, Figure 3). At the same 
time, the compound 14 was fully inactive in the presence of CCL5. This CCL4-dependence indicates a 
slightly different CCR5 receptor binding pocket for compound 26b compared to TAK-779, since TAK-
779 displays a negative allosteric modulation with both chemokines CCL4 and CCL5. Of note, probe-
dependent negative allosteric modulators (NAM) of CXCR3 receptors were recently reported.16,17 
Probe-dependent allosteric modulation provides a promising strategy for fine tuning of the chemokine 
response and corresponding ligands are therefore of great interest for drug development in the 
chemokine receptor field. If we consider that 14 binds to a different subpocket than TAK-779, the lack 
of CCR5 affinity of 14 in a radioligand binding assay is not surprising, as it would not compete with 
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[3H]TAK-779. In the benzene ring of the sulfathiazole-derived amide 16 further substituents are also 
missing. However, 16 does not induce similar effects as 14, which is probably due to the lacking basic 
amino moiety.  
 
3. Conclusion 
The introduction of the p-tolyl group at 7-position of the 2-benzazepine scaffold seems to be crucial for 
CCR2 receptor interactions. In the CCR2 binding assay and the Ca2+ flux assay, the 7-p-tolyl derivative 
26b displayed moderate affinity (IC50 = 387 nM) and activity (IC50 = 140 nM). Obviously the CCR2 
receptor is able to accommodate at the different structure of the 2-benzazepinone 26b compared to the 
structures of the lead compounds TAK-779 and TAK-652. Despite the different conformations of the 
scaffolds, the isobutyl moieties of TAK-652 and 26b adopt similar orientations, which might explain the 
moderate interactions of 26b with the CCR2 receptor. The corresponding 8-p-tolyl regioisomer 26a was 
approx. 20-fold less potent in both assays, other substituents at the 2-benzazepine framework were not 
tolerated by the CCR2 receptor. 
 
The synthesized 2-benzazepinones did not show any affinity towards the CCR5 receptor in the 
[3H]TAK-779 competition assay. Despite the absence of TAK-779 displacement at CCR5 receptors, the 
naked 2-benzazepinone 14 led to an increased production of cAMP after stimulation of the CCR5 
receptor with CCL4. This probe-dependent positive allosteric modulation of the CCR5 receptor, which 







4. Experimental Part 
4.1. General 
Unless otherwise noted, moisture sensitive reactions were conducted under dry nitrogen. THF was dried 
with sodium/benzophenone, CH2Cl2 with calcium hydride and both were freshly distilled before use. 
Thin layer chromatography (tlc): Silica gel 60 F254 plates (Merck). Flash chromatography (fc): Silica gel 
60, 40–64 µm (Merck); parentheses include: diameter of the column, length of column, fraction size, 
eluent, Rf value. Melting point: melting point system MP50 (Mettler Toledo), uncorrected. IR: IR 
spectrophotometer 480Plus FT-ATR-IR (Jasco). 1H NMR (400 MHz), 13C NMR (100 MHz): Mercury 
plus 400 spectrometer (Varian); δ in ppm related to tetramethylsilane; coupling constants are given with 
0.5 Hz resolution. MS: APCI = atmospheric pressure chemical ionization: MicroTOFQII (Bruker 
Daltonics), ESI = electro spray ionization: MicroTof (Bruker Daltonics, Bremen), calibration with 
sodium formate clusters before measurement. Deviations of the found exact masses from the calculated 
exact masses were 5 mDa or less, unless otherwise stated. The data were analyzed with DataAnalysis 
(Bruker).  
 
4.2. HPLC methods 
4.2.1. Method 1: Purity of compounds 
Merck Hitachi equipment; UV detector: L-7400; autosampler: L-7200; pump: L-7100; degasser: 
L-7614; Method A: column: LiChrospher® 60 RP-select B (5 µm), 250-4 mm cartridge; flow rate: 1.00 
mL/min; injection volume: 5.0 µL; detection λ = 210 nm; solvents: A: water with 0.05% (v/v) 
trifluoroacetic acid; B: acetonitrile with 0.05% (v/v) trifluoroacetic acid: gradient elution: (A %): 0-4 
min: 90% , 4-29 min: gradient from 90% to 0%, 29-31 min: 0%, 31-31.5 min: gradient from 0% to 90%, 




4.2.2. Method 2: Preparative HPLC 
Merck Hitachi equipment; UV detector: L-7400; autosampler: L-7200; pump: L-7100; interface: D-
7000; data acquisition: HSM Software (LaChrom, Merck-Hitachi); solvent: acetonitrile : H2O 70:30; 
column: Phenomenex® Gemini 5 μm C18 110A, 250 – 21.2 mm; flow rate: 10.00 mL/min; injection 
volume 500.0 μL; detection: wavelength: 254 nm, stop time: 60.0 min. 
 
4.3. Synthetic procedures 
4.3.1. Methyl 3-(isobutylamino)propanoate (6•HCl) 
Methyl 4-acrylate (9.81 g, 114 mmol, 15.0 mL) was added slowly to a vigorously stirred mixture of 
isobutylamine (10 g, 137 mmol, 13.6 mL) and sodium methanolate (123 mg, 2.28 mmol) in methanol 
(70 mL). The mixture was stirred for 2 h at rt, concentrated in vacuo and the residue was purified by fc 
(Ø = 4 cm, h = 16 cm, cyclohexane / ethyl acetate = 1 : 2 + 1% triethylamine, Rf = 0.71) to give a 
colorless oil. The oil was dissolved in Et2O and 2 M HCl in Et2O was added to the solution. A colorless 
precipitate was formed, which was separated by filtration with Et2O to give 6 as a HCl-salt. Colorless 
solid, mp 187 °C, yield 23.8 g (89%). C8H18ClNO2, Mr = 195.7.  Exact MS (APCI): m/z = 160.1380 
(calcd. 160.1332 for C8H18NO2 [MH+]). 1H NMR (DMSO-d6): δ [ppm] = 0.94 (d, J = 6.7 Hz, 6H, 
NCH2CH(CH3)2), 1.90 - 2.05 (m, 1H, NCH2CH(CH3)2), 2.75 (d, J = 7.1 Hz, 2H, NCH2CH(CH3)2), 2.83 
(t, J = 7.5 Hz, 2H, CH2CH2CO2CH3), 3.12 (t, J = 7.4 Hz, 2H, CH2CH2CO2CH3), 3.64 (s, 3H, CO2CH3), 
8.88 (s, 2H, NH2). 13C NMR (DMSO-d6): δ [ppm] = 19.9 (2C, NCH2CH(CH3)2), 25.2 (1C, 
NCH2CH(CH3)2), 29.8 (1C, CH2CH2CO2CH3), 42.6 (1C, CH2CH2CO2CH3), 51.7 (1C, CO2CH3), 53.7 
(1C, NCH2CH(CH3)2), 170.4 (1C, CO2CH3). IR (neat): ν [cm-1] = 1736 (C=O), 1593 (C-N). 
 
4.3.2. Methyl 2-{N-isobutyl-N-[2-(methoxycarbonyl)ethyl]-carbamoyl}-benzoate (8) 
Monomethyl phthalate (7, 6.24 g, 34.6 mmol) was added to a vigorously stirred solution of SOCl2 (6.18 
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g, 52 mmol, 3.77 mL) in CH2Cl2 (20 mL) and the mixture was heated to reflux for 1.5 h. The reflux 
condenser was replaced by a Liebig micro distillation apparatus to remove CH2Cl2 and SOCl2. The 
residue was dissolved in CH2Cl2 (20 mL). Then pyridine (8.21 g, 104 mmol, 8.4 mL, 3 equiv.) and 
6•HCl (8.13 g, 41.5 mmol, 1.2 equiv.) were added under ice cooling. After 4 h, the mixture was 
concentrated in vacuo, the residue was suspended in sat. NaHCO3 and the mixture was extracted with 
CH2Cl2 (3 x 50 mL). The combined organic layers were dried (Na2SO4), concentrated in vacuo and the 
residue was purified by fc (Ø = 8 cm, h = 16 cm, cyclohexane / ethyl acetate = 2 : 1, Rf = 0.45) to give 8 
as a colorless solid, mp 62 °C, yield 7.12 g (64%). C17H23NO5, Mr = 321.4. Exact MS (APCI): m/z = 
322.1659 (calcd. 322.1649 for C17H24NO5 [MH+]). 1H NMR (CDCl3): δ [ppm] = 0.76 (d, J = 6.7 Hz, 6H, 
NCH2CH(CH3)2), 1.81 – 1.92 (m, 1H, NCH2CH(CH3)2), 2.79 – 2.91 (m, 4H, CH2CH2CO2CH3), 3.72 (s, 
3H, CH2CH2CO2CH3), 3.73 – 3.86 (m, 2H, NCH2CH(CH3)2), 3.86 (s, 3H, ArCO2CH3), 7.28 (dd, J = 
7.9/1.0 Hz, 1H, Ar-H), 7.40 – 7.45 (m, 1H, Ar-H), 7.53 – 7.56 (m, 1H, Ar-H), 7.97 – 8.05 (m, 1H, Ar-
H). 13C NMR (CDCl3): δ [ppm] = 20.1 (2C, NCH2CH(CH3)2), 27.1 (1C, NCH2CH(CH3)2), 31.4 (1C, 
CH2CH2CO2CH3), 41.2 (1C, NCH2CH(CH3)2), 51.7 (1C, CH2CH2CO2CH3), 52.3 (1C, ArCO2CH3), 56.2 
(1C, CH2CH2CO2CH3), 127.7 (1C, Ar-C), 128.5 (1C, Ar-C), 128.7 (1C, Ar-C), 130.4 (1C, Ar-C), 132.6 
(1C, Ar-C), 132.7 (1C, Ar-C), 165.8 (1C, ArCO2CH3), 171.4 (1C, CONR2), 172.8 (1C, CO2CH3). IR 
(neat): ν [cm-1] = 1725 (C=O), 1625 (NC=O). 
 
4.3.3. Methyl 2-isobutyl-5-hydroxy-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxylate (9) 
Under ice cooling a dispersion of NaH (60% w/w in mineral oil 540 mg, 13.5 mmol) was added slowly 
to a solution of the amide 8 (1.41 g, 4.5 mmol) in THF (20 mL) and left to stir for 0.5 h, then mixture 
was heated to reflux for 1.5 h. After cooling to rt the mixture was concentrated in vacuo and the residue 
was suspended in 1 M HCl. The aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined 
organic layers were dried (Na2SO4), concentrated in vacuo and the residue was purified by automatic fc 
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(Biotage®, Cartridge SNAP 100 g, cyclohexane / ethyl acetate, Rf = 0.35 (cyclohexane / ethyl acetate = 2 
: 1)) to give the 2-benzazepine 9 as a pale yellow solid, mp 84 °C, yield 750 mg (58%). C16H19NO4, 
Mr = 289.3. Exact MS (APCI): m/z = 290.1387 (calcd. 290.1392 for C16H20NO4 [MH+]). 1H NMR 
(CDCl3): δ [ppm] = 0.95 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 2.00 – 2.13 (m, 1H, NCH2CH(CH3)2), 
3.23 - 3.38 (m, 1H, NCH2CH(CH3)2), 3.45 - 3.61 (m, 1H, NCH2CH(CH3)2), 3.68 - 3.82 (m, 1H, 3-CH2), 
3.90 (s, 3H, CO2CH3), 4.01 - 4.17 (m, 1H, 3-CH2), 7.53 - 7.61 (m, 2H, Ar-H), 7.84 - 7.90 (m, 1H, Ar-H), 
7.98 - 8.03 (m, 1H, Ar-H), 12.56 (s, 1H, OH). 13C NMR (CDCl3): δ [ppm] = 20.3 (2C, NCH2CH(CH3)2), 
27.7 (1C, NCH2CH(CH3)2), 43.6 (1C, C-3), 52.4 (1C, CO2CH3), 55.8 (1C, NCH2CH(CH3)2), 102.3 (1C, 
C-4), 127 (1C, Ar-C), 130.6 (1C, Ar-C), 130.9 (1C, Ar-C), 131.2 (1C, Ar-C), 131.3 (1C, Ar-C), 136.3 
(1C, Ar-C), 167.8 (1C, CONR2), 170.4 (1C, CO2CH3), 171.2 (1C, C-5). IR (neat): ν [cm-1] = 1728 
(C=O), 1632 (C=O), 1611 (NC=O). 
 
4.3.4. Methyl 2-isobutyl-5-hydroxy-1-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-carboxylate (10) 
NaBH4 (523 mg, 13.8 mmol) was added slowly to a solution of the enol ester 9 (2.0 g, 6.91 mmol) in 
abs. H3COH (50 mL) under ice cooling. After 1 h, 1 M HCl (50 mL) was added and the mixture was 
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried (Na2SO4), concentrated in 
vacuo and the residue was purified by fc (Ø = 3 cm, h = 16 cm, cyclohexane / ethyl acetate = 4 : 1, Rf = 
0.18) to give 10 as a colorless solid, mp 154 °C, yield 1.16 g (58%). C16H21NO4, Mr = 291.4. Exact MS 
(APCI): m/z = 292.1590 (calcd. 292.1543 for C16H22NO4 [MH+]). 1H NMR (CDCl3): δ [ppm] = 0.92 (d, 
J = 6.7 Hz, 6H, NCH2CH(CH3)2), 1.98 – 2.06 (m, 1H, NCH2CH(CH3)2), 3.19 – 3.36 (m, 5H, 
NCH2CH(CH3)2, 3-CH2, 4-CH), 3.68 (s, 3H, CO2CH3), 4.60 (d, J = 6.7 Hz, 1H, 5-CH), 7.30 – 7.40 (m, 
1H, Ar-H), 7.41 – 7.48 (m, 2H, Ar-H), 7.63 (d, J = 7.3 Hz, 1H, Ar-H). A signal for OH proton is not 
seen in the spectrum. 13C NMR (CDCl3): δ [ppm] = 20.5 (2C, NCH2CH(CH3)2), 27.8 (1C, 
NCH2CH(CH3)2), 48.1 (1C, NCH2CHCO2CH3), 51.6 (1C, C-3), 52.1 (1C, CO2CH3), 55.1 (1C, C-4), 
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70.2 (1C, C-5), 125.1 (1C, Ar-C), 128.2 (1C, Ar-C), 128.5 (1C, Ar-C), 130.9 (1C, Ar-C), 133.2 (1C, Ar-
C), 138.1 (1C, Ar-C), 171.1 (1C, C-1), 171.5 (1C, CO2CH3). IR (neat): ν [cm-1] = 3221 (-OH), 1725 
(C=O), 1620 (NC=O). 
 
4.3.5. Methyl 2-isobutyl-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxylate (11) 
Under ice cooling CH3SO2Cl (1117 mg, 9.75 mmol) was added to a solution of β-hydroxy ester 10 
(943.5 mg, 3.25 mmol) and triethylamine (986 mg, 9.75 mmol) in CH2Cl2 (20 mL). The reaction mixture 
was stirred overnight at rt. Then DBU (2.47 g, 16.3 mmol) was added under ice cooling. The reaction 
mixture was stirred for 1 h at rt. Then 1 M HCl was added and the mixture was extracted with CH2Cl2 (3 
x 50 mL). The combined organic layers were dried (Na2SO4), concentrated in vacuo and the residue was 
purified by fc (Ø = 3 cm, h = 16 cm, cyclohexane / ethyl acetate = 4 : 1, Rf = 0.6) to give 11 as a 
colorless solid, mp 69 °C, yield 679 mg (76%). C16H20NO3, Mr = 273.3. Exact MS (APCI): m/z = 
274.1500 (calcd. 274.1432 for C16H21NO3 [MH+]). 1H NMR (CDCl3): δ [ppm] = 0.93 (d, J = 6.7 Hz, 6H, 
NCH2CH(CH3)2), 2.01 – 2.13 (m, 1H, NCH2CH(CH3)2), 3.44 (d, J = 7.6 Hz, 2H, NCH2CH(CH3)2), 3.88 
(s, 3H, CO2CH3), 3.97 (s, 2H, 3-CH2), 7.34 (dd, J = 5.9/3.7 Hz, 1H, Ar-H), 7.50 (dd, J = 6.0/3.7 Hz, 2H, 
Ar-H), 7.82 (s, 1H, 5-CH), 8.09 (dd, J = 5.8/3.5 Hz, 1H, Ar-H). 13C NMR (CDCl3): δ [ppm] = 20.2 (2C, 
NCH2CH(CH3)2), 27.7 (1C, NCH2CH(CH3)2), 44.4 (1C, C-3), 52.6 (1C, NCH2CH(CH3)2), 56.3 (1C, 
CO2CH3), 129.7 (1C, Ar-C), 129.9 (1C, Ar-C), 130.5 (1C, Ar-C), 131.8 (1C, Ar-C), 132.9 (1C, Ar-C), 
133.2 (1C, Ar-C), 136.8 (1C, C-4), 141.7 (1C, C-5), 166.1 (1C, CO2CH3), 168.1 (1C, C-1). IR (neat): ν 
[cm-1] = 2924 (C-Haliph.), 1725 (C=O), 1597 (C=C). 
 
4.3.6. 2-Isobutyl-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxylic acid (12) 
The ester 11 (120 mg, 0.44 mmol) was dissolved in H3COH (10 mL) and 5 M NaOH (10 mL) was 
added. The mixture was heated to reflux for 40 min. After cooling down to 0 °C, the mixture was 
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acidified with conc. HCl (2.5 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic 
layers were dried (Na2SO4) and concentrated in vacuo to give the acid 12. Colorless solid, mp 192 °C, 
yield 114 mg (100%). C15H17NO3, Mr = 259.3. Rf = 0.12 (cyclohexane / ethyl acetate = 2 : 1). Exact MS 
(APCI): m/z = 260.1285 (calcd. 260.1281, for C15H18NO3 [MH+]). 1H NMR (methanol-d4): δ [ppm] = 
0.94 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 2.05 - 2.18 (m, 1H, NCH2CH(CH3)2), 3.46 (d, J = 7.6 Hz, 2H, 
NCH2CH(CH3)2), 4.01 (s, 2H, 3-CH2), 7.50 (dd, J = 7./1.5 Hz, 1H, Ar-H), 7.53 - 7.63 (m, 2H, Ar-H), 
7.91 (s, 1H, 5-H), 7.99 (dd, J = 7.7/1.6 Hz, 1H, Ar-H). A signal for COOH proton is not seen in the 
spectrum. 13C NMR (methanol-d4): δ [ppm] = 20.4 (2C, N-CH2-CH-(CH3)2), 28.8 (1C, N-CH2-CH-
(CH3)2), 45.4 (1C, C-3), 57.2 (1C, N-CH2-CH-(CH3)2), 130.7 (1C, Ar-C), 131.1 (1C, Ar-C), 132.0 (1C, 
Ar-C), 132.1 (1C, Ar-C), 135.0 (1C, C-4), 135.30 (1C, Ar-C), 137.11 (1C, Ar-C), 142.00 (1C, C-5), 
168.2 (1C, CO2CH3), 170.2 (1C, C-1). IR (neat): ν [cm-1] = 2937 (C-Haliph.), 1715 (C=O), 1600 (C=C). 




Amine 13 (113 mg, 0.44 mmol) was added to a vigorously stirred mixture of acid 12 (113.8 mg, 0.44 
mmol), NEt3 (89.1 mg, 0.88 mmol) and HATU (182.5 mg, 0.48 mmol) in abs. THF (5 mL). The mixture 
was stirred overnight at rt. Then the mixture was concentrated in vacuo. Saturated NaHCO3-solution (20 
mL) was added to the residue and the mixture was extracted with CH2Cl2 (3 x 20 mL). The combined 
organic layers were concentrated in vacuo to give a yellow solid, which was purified by fc (Ø = 1.5 cm, 
h = 20 cm, CH2Cl2 : H3COH = 9 : 1 + 1% NH3, V = 30 mL, Rf = 0.66) and then by automatic fc 
(Biotage®, SNAP Cartridge KP-C18-HS 30 g, water/acetonitrile) to give 14. Colorless solid, yield 97 mg 
(48%). C28H35N3O3, Mr = 461.6. Exact MS (APCI): m/z = 462.2709 (calcd. 462.2678 for C28H36N3O3 
[MH+]). 1H NMR (CDCl3): δ [ppm] = 0.84 (d, J = 6.6 Hz, 6H, NCH2CH(CH3)2), 1.64 – 1.77 (m, 2H, 3-
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CHpyran, 5-CHpyran), 1.77 – 1.86 (m, 2H, 3-CHpyran, 5-CHpyran), 1.91 – 2.04 (m, 1H, NCH2CH(CH3)2), 
2.26 (s, 3H, CH3), 2.70 – 2.83 (m, 1H, 4-CHpyran), 3.34 (d, J = 6.8 Hz, 2H, NCH2CH(CH3)2), 3.39 (d, J = 
11.4 Hz, 2H, 2-CHpyran, 6-CHpyran), 3.64 (s, 2H, CH2N), 3.91 (s, 2H, CH2NCO), 4.04 (dd, J = 11.2/3.3 
Hz, 2H, 2-CHpyran, 6-CHpyran), 6.88 (d, J = 7.1 Hz, 1H, 6-CH), 7.13 (s, 1H, 5-CH), 7.32 (t, J = 8.3 Hz, 
3H, 3-CHaniline, 5-CHaniline, 7-CH), 7.41 (t, J = 7.5 Hz, 1H, 8-CH), 7.76 (d, J = 8.4 Hz, 2H, 2-CHaniline, 6-
CHaniline), 7.98 (d, J = 7.8 Hz, 1H, 9-CH), 9.22 (s, 1H, NH). 13C NMR (CDCl3): δ [ppm] = 20.1 (2C, 
NCH2CH(CH3)2), 27.7 (1C, NCH2CH(CH3)2), 29.1 (2C, 3-Cpyran, 5-Cpyran), 37.4 (1C, CH3), 44.6 (1C, 3-
C), 56.2 (1C, NCH2CH(CH3)2), 57.4 (1C, CH2N), 59.9 (1C, 4-Cpyran), 67.6 (2C, 2-Cpyran, 6-Cpyran), 120.3 
(2C, 2-Caniline, 6-Caniline), 129.0 (1C, 8-C), 129.4 (1C, 6-C), 129.7 (2C, 3-Caniline, 5-Caniline), 130.7 (1C, C-
8), 130.7 (1C, C-9a), 130.9 (1C, C-9), 135.1 (1C, C-7), 134.4 (1C, C-4aniline), 135.7 (1C, C-5a), 137.8 
(1C, C-1aniline), 164.9 (1C, CONH), 168.6 (1C, C-1). The signal for C-4 is not seen in the spectrum. IR 
(neat): ν [cm-1] = 3300 (NH), 2939 (CHaliph.), 1650 (C=O), 1022 (C-O). HPLC (method 1): tR = 20.62 




Sulfathiazole (15, 47 mg, 0.19 mmol, 1 equiv.) was added to a vigorously stirred mixture of 12 (48 mg, 
0.19 mmol, 1 equiv.), NEt3 (51 µL, 38 mg, 0.37 mmol, 2 equiv.) and HATU (77 mg, 0.20 mmol, 
1.1 equiv.) in abs. THF (3 mL). The mixture was stirred overnight at rt. The solvent was removed in 
vacuo and a saturated solution of NaHCO3 (10 mL) was added to the residue. The mixture was extracted 
with CH2Cl2 (2 x 10 mL) and ethyl acetate (2 x 10 mL). The combined organic layers were dried 
(Na2SO4) and concentrated in vacuo to give the crude product as yellow oil, which was purified by fc 
(Ø = 2 cm, h = 16 cm, CH2Cl2 : H3COH = 97 : 3 + 1% NH3, V = 10 mL, Rf = 0.34 (CH2Cl2 : 
H3COH = 95 : 5 + 1% NH3)). Colorless oil, yield 7 mg (8%). C24H24N4O4S2, Mr = 496.6. Exact mass 
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(APCI): m/z = 497.1296 (calcd. 497.1312 for C24H25N4O4S2 [MH+]). 1H NMR (DMSO-d6): δ [ppm] = 
0.85 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 1.90 – 1.96 (m, 1H, NCH2CH(CH3)2), 3.36 (d, J = 7.5 Hz, 
2H, NCH2CH(CH3)2), 3.93 (s, 2H, 3-CH2), 6.83 (d, J = 4.6 Hz, 1H, 5-CHthiazole), 7.26 (d, J = 4.6 Hz, 1H, 
4-CHthiazole), 7.55 (m, 2H, 6-CH, 8-CH), 7.62 (td, J = 7.7/1.4 Hz, 1H, 7-CH), 7.77 (s, 1H, 5-CH), 7.79 (d, 
J = 8.8 Hz, 2H, 2-CHphenyl, 6-CHphenyl), 7.88 (d, J = 8.8 Hz, 2H, 3-CHphenyl, 5-CHphenyl), 7.93 (m, 1H, 9-
CH), 10.55 (s, 1H, NH), 12.70 (s, 1H, SO2NH). 13C NMR (DMSO-d6): δ [ppm] = 19.9 (2C, 
NCH2CH(CH3)2), 27.2 (1C, NCH2CH(CH3)2), 44.1 (1C, C-3), 55.0 (1C, NCH2CH(CH3)2), 108.1 (1C, C-
5thiazole), 119.6 (2C, C-2phenyl, C-6phenyl), 124.4 (1C, C-4thiazole), 126.8 (2C, C-3phenyl, C-5phenyl), 129.1 (1C, 
C-8), 129.6 (1C, C-6), 130.5 (1C, C-7), 131.0 (1C, C-9), 133.1 (1C, C-5a), 135.9 (1C, C-9a), 136.2 (1C, 
C-5), 136.8 (1C, C-4phenyl), 137.0 (1C, C-4), 142.2 (1C, C-1phenyl), 165.0 (1C, CONH), 167.0 (1C, C-1),  
168.7 (1C, C-2thiazole). IR (neat): ν [cm-1] = 3433 (CONH), 1053 (SO2), 1662 (C=O). HPLC (method 1): 
tR = 18.68 min, purity 96.8%. 
 
4.3.9. Methyl 2-isobutyl-1-oxo-8-(p-tolyl)-2,3-dihydro-1H-2-benzazepine-4-carboxylate (24a) 
Under a permanent flow of N2, ester 23a (160 mg, 0.45 mmol), PdCl2(dppf) (22 mg, 5 mol %), KOAc 
(104 mg, 1 mmol) and 4-methylbenzeneboronic acid (79 mg, 0.5 mmol) were suspended in dry 
dimethoxyethane (10 mL). The Schlenk tube was sealed and heated to 100 °C for 12 h. After cooling 
down to rt, the mixture was filtered through a short silica pad (ethyl acetate). The filtrate was 
concentrated in vacuo to give the crude product as a brown oil, which was purified by automatic fc 
(Biotage®, SNAP 50 g, cyclohexane / ethyl acetate) to give 24a. Colorless solid, mp 124 °C, yield 82 mg 
(50%). C23H25NO3, Mr = 363.5. 1H NMR (CDCl3): δ [ppm] = 0.92 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 
2.08 – 2.17 (m, 1H, NCH2CH(CH3)2), 2.40 (s, 3H, CH3), 3.51 (d, J = 7.6 Hz, 2H, NCH2CH(CH3)2), 3.95 
(s, 3H, CO2CH3), 4.14 (s, 2H, 3-CH2), 7.28 – 7.36 (m, 2H, 3-CHtolyl, 5-CHtolyl), 7.47 – 7.65 (m, 3H, 2-
CHtolyl, 6-CHtolyl), 7.64 (dd, J = 8.2/2.0 Hz, 1H, 7-CH), 7.71 (dd, J = 8.2/2.1 Hz, 1H, 6-CH), 7.89 (s, 1H, 
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5-CH), 8.20 (s, 1H, 9-CH). 13C NMR (CDCl3): δ [ppm] = 20.2 (2C, NCH2CH(CH3)2), 21.3 (1C, CH3), 
27.8 (1C, NCH2CH(CH3)2), 44.5 (1C, C-3), 52.6 (1C, CO2CH3), 56.4 (1C, NCH2CH(CH3)2), 124.3 (1C, 
C-7), 127.1 (2C, C-2tolyl, C-6tolyl), 128.1 (1C, C-4), 130.3 (2C, C-3tolyl, C-5tolyl), 132.5 (1C, C-9), 132.9 
(1C, C-9a), 134.6 (1C, C-4tolyl), 138.0 (1C, C-5a), 138.8 (1C, C-1tolyl), 141.9 (1C, C-6), 149.2 (1C, C-8), 
168.1 (1C, CO2CH3), 170.0 (1C, C-1). IR (neat): ν [cm-1] = 2937 (C-Haliph.), 1728 (C=Oamide), 1600 
(C=C). 
 
4.3.10. Methyl 2-isobutyl-1-oxo-7-(p-tolyl)-2,3-dihydro-1H-2-benzazepine-4-carboxylate (24b) 
Under a permanent flow of N2, ester 23b (160 mg, 0.45 mmol), PdCl2(dppf) (22 mg, 5 mol%), KOAc 
(104 mg, 1 mmol) and 4-methylbenzeneboronic acid (79 mg, 0.5 mmol) were suspended in dry 
dimethoxyethane (10 mL). The Schlenk tube was sealed and heated to 100 °C for 12 h. After cooling 
down to rt, the mixture was filtered through a short silica pad (ethyl acetate). The filtrate was 
concentrated in vacuo and purified by automatic fc (Biotage®, SNAP 50 g, cyclohexane / ethyl acetate) 
to give 24b. Colorless solid, mp 128 °C, yield 95 mg (58%). C23H25NO3, Mr = 363.5. 1H NMR (CDCl3): 
δ [ppm] = 0.94 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 2.02 – 2.15 (m, 1H, NCH2CH(CH3)2), 2.41 (s, 3H, 
CH3), 3.46 (d, J = 7.6 Hz, 2H, NCH2CH(CH3)2), 3.89 (s, 3H, CO2CH3), 4.02 (s, 2H, 3-CH2), 7.26 – 7.30 
(m, 2H, 3-CHtolyl, 5-CHtolyl), 7.47 – 7.61 (m, 3H, 2-CHtolyl, 6-CHtolyl, 6-CH), 7.71 (dd, J = 8.2/1.8 Hz, 
1H, 8-CH), 7.88 (s, 1H, 5-CH), 8.15 (d, J = 8.2 Hz, 1H, 9-CH). 13C NMR (CDCl3): δ [ppm] = 20.2 (2C, 
NCH2CH(CH3)2), 21.3 (1C, CH3), 27.8 (1C, NCH2CH(CH3)2), 44.5 (1C, C-3), 52.6 (1C, CO2CH3), 56.4 
(1C, NCH2CH(CH3)2), 127.1 (2C, C-2tolyl, C-6tolyl), 128.1 (1C, C-8), 128.4 (1C, C-6), 129.9 (2C, C-3tolyl, 
C-5tolyl), 132.4 (1C, C-9), 133.6 (1C, C-9a), 135.1 (1C, C-5a), 136.6 (1C, C-4tolyl), 138.3 (1C, C-1tolyl), 
141.9 (1C, C-5), 143.3 (1C, C-7), 166.1 (1C, CO2CH3), 168.0 (1C, C-1). IR (neat): ν [cm-1] = 2937 (C-




Mixture of 24a and 24b: As described above, a mixture of the regioisomers 23a and 23b (120 mg, 0.34 
mmol) was reacted with 4-methylbenzeneboronic acid (51 mg, 0.37 mmol). Pale yellow oil, yield 74 mg 




The ester 24a (90 mg, 0.25 mmol) was dissolved in H3COH (10 mL) and 5 M NaOH (10 mL) was 
added. The mixture was heated to reflux for 30 min. After cooling down to 0 °C, the mixture was 
acidified with conc. HCl to give a precipitate. The aqueous layer was extracted with ethyl acetate (3 x 
25 mL), the combined organic layers were dried (Na2SO4), added to the precipitate and concentrated in 
vacuo to give the acid 25a. Colorless solid, yield 87 mg (97%). C22H23NO3, Mr = 349.4. Amine 13 (64 
mg, 0.25 mmol, 1 equiv.) was added to a vigorously stirred mixture of acid 25a (87 mg, 0.25 mmol, 1 
equiv.), trimethylamine (51 mg, 0.5 mmol, 2 equiv.) and HATU (105 mg, 0.28 mmol, 1.1 equiv.) in abs. 
THF (10 mL). The mixture was stirred overnight at rt. Then the mixture was concentrated in vacuo. Sat. 
NaHCO3-solution (20 mL) was added to the residue and the mixture was extracted with CH2Cl2 (3 x 20 
mL). The combined organic layers were concentrated in vacuo to give a yellow oil, which was first 
purified by automatic fc (Biotage®, SNAP Cartridge KP-C18-HS 30g, water/acetonitrile) to give 26a. 
Pale yellow solid, yield 54 mg (39%). Exact MS (APCI): m/z = 552.3236 (calcd. 552.3221 for 
C35H41N3O3 [MH+]). 1H NMR (CDCl3): δ [ppm] = 0.86 (d, J = 6.6 Hz, 6H, NCH2CH(CH3)2), 1.70 – 
1.84 (m, 2H, 3-CH2pyran, 5-CH2pyran), 1.91 (d, J = 11.6 Hz, 2H, 3-CH2pyran, 5-CH2pyran), 1.95 – 2.07 (m, 
1H, NCH2CH(CH3)2), 2.36 (s, 3H, CH3tolyl), 2.40 (s, 3H, NCH3), 3.09 (m, 1H, 4-CHpyran), 3.31 (m, 2H, 
2-CH2pyran, 6-CH2pyran) 3.35 (d, 2H, J = 7.6 Hz, NCH2CH(CH3)2), 3.90 (s, 2H, 3-CH2), 3.95 (s, 2H, 
NCH2), 4.03 (dd, J = 11.2/4.1 Hz, 2H, 2-CH2pyran, 6-CH2pyran), 7.13 (s, 1H, 5-CH), 7.16 (d, J = 8.1 Hz, 
2H, 3-CHtolyl, 5-CHtolyl), 7.17 – 7.20 (m, 1H, 6-CH), 7.35 (d, J = 6.2 Hz, 2H, 2-CHtolyl, 6-CHtoly), 7.40 (d, 
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J = 8.3 Hz, 2H, 3-CHphenyl, 5-CHphenyl), 7.62 (dd, J = 8.2/1.8 Hz, 1H, 7-CH), 7.82 (d, J = 8.2 Hz, 2H, 2-
CHphenyl, 6-CHphenyl), 8.08 (s, 1H, 9-CH), 9.62 (s, 1H, NH). 13C NMR (CDCl3): δ [ppm] = 20.2 (2C, 
NCH2CH(CH3)2), 21.3 (1C, CH3tolyl), 27.7 (1C, NCH2CH(CH3)2), 27.9 (2C, C-3pyran, C-5pyran), 35.9 (1C, 
NCH3), 44.6 (1C, PhCH2N), 56.23 (1C NCH2CH(CH3)2), 56.5 (1C, C-3), 59.5 (1C, C-4pyran), 67.0 (2C, 
C-2pyran, C-6pyran), 120.6 (2C, C-2phenyl, C-6phenyl), 126.9 (2C, C-2tolyl, C-6tolyl), 127.0 (1C, C-7), 127.1 
(1C, C-5), 127.2 (1C, C-5a), 127.4 (1C, C-6), 129.2 (1C, C-4phenyl), 129.7 (1C. C-1tolyl), 129.8 (2C, C-
3tolyl, C-5tolyl), 130.8 (2C, C-3phenyl, C-5phenyl), 131.8 (1C, C-9), 134.2 (1C, C-8), 138.3 (1C, C-4tolyl), 
139.2 (1C, C-1phenyl), 141.4 (1C, C-4), 143.0 (1C, C-9a), 165.1 (1C, CONH), 168.5 (1C, C-1). IR (neat): 





The ester 24b (82 mg, 0.23 mmol) was dissolved in H3COH (10 mL) and 5 M NaOH (10 mL) was 
added. The mixture was heated to reflux for 30 min. After cooling down to 0 °C, the mixture was 
acidified with conc. HCl to give a precipitate. The aqueous layer was extracted with EtOAc (3 x 25 mL), 
the combined organic layers were dried (Na2SO4), added to the precipitate and concentrated in vacuo to 
give the acid 25b. Colorless solid, yield 79 mg (97%). C22H23NO3 Mr = 349.4 g/mol. Amine 13 (58 mg, 
0.23 mmol) was added to a vigorously stirred mixture of acid 25b (79 mg, 0.23 mmol), triethylamine 
(46 mg, 0.45 mmol) and HATU (95 mg, 0.25 mmol) in THF (10 mL). The mixture was stirred overnight 
at rt. Then the mixture was concentrated in vacuo. Saturated NaHCO3 solution (20 mL) was added to the 
residue and the mixture was extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were 
concentrated in vacuo to give a yellow oil, which was purified by automatic fc (Biotage®, SNAP KP-
C18-HS 30 g, water/acetonitrile) to give 26b. Pale yellow solid, yield 42 mg (34%). C35H41N3O3, 
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Mr = 551.7. Exact MS (APCI): m/z = 552.3236 (calcd. 552.3221 for C35H41N3O3 [MH+]). 1H NMR 
(CDCl3): δ [ppm] = 0.88 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 1.72 – 1.79 (m, 2H, 3-CH2pyran, 5-
CH2pyran), 1.86-1.92 (d, J = 11.6 Hz, 2H, 3-CH2pyran, 5-CH2pyran), 2.03 (non, J = 6.9 Hz, 1H, 
NCH2CH(CH3)2), 2.36 (s, 3H, NCH3), 2.40 (s, 3H, CH3tolyl), 2.89 – 3.02 (m, 1H, 4-CHpyran), 3.30 – 3.37 
(m, 2H, 2-CH2pyran, 6-CH2pyran), 3.40 (d, J = 7.6 Hz, 2H, NCH2CH(CH3)2), 3.81 (s, 2H, NCH2), 3.99 (s, 
2H, 3-CH2), 4.04 (dd, J = 11.3/3.8 Hz, 2H, 2-CH2pyran, 6-CH2pyran), 7.18 (d, J = 7.9 Hz, 2H, 3-CHtolyl, 5-
CHtolyl), 7.25 (m, 1H, 6-CH), 7.38 (m, 3H, 5-CH, 2-CHphenyl, 6-CHphenyl), 7.42 (d, J = 8.1 Hz, 2H, 3-
CHphenyl, 5-CHphenyl), 7.64 (dd, J = 8.2/1.8 Hz, 1H, 8-CH), 7.78 (d, J = 8.3 Hz, 2H, 2-CHphenyl, 6-
CHphenyl), 8.10 (d, J = 8.2 Hz, 1H, 9-CH), 9.23 (s, 1H, NH). 13C NMR (CDCl3): δ [ppm] = 20.2 (2C, 
NCH2CH(CH3)2), 21.3 (1C, CH3tolyl), 27.7 (1C, NCH2CH(CH3)2), 28.3 (2C, C-3pyran, C-5pyran), 36.5 (1C, 
NCH3), 44.7 (1C, C-3), 56.2 (1C NCH2CH(CH3)2), 56.9 (1C, PhCH2N), 59.7 (1C, C-4pyran), 67.3 (2C, C-
2pyran, C-6pyran), 120.5 (2C, C-2phenyl, C-6phenyl), 127.0 (2C, C-2tolyl, C-6tolyl), 127.3 (1C, C-6), 127.5 (1C, 
C-8), 129.8 (2C, C-3tolyl, C-5tolyl), 130.5 (2C, C-3phenyl, C-5phenyl), 131.9 (1C, C-9), 133.8 (1C, C-5a), 
134.4 (1C, C-9a), 135.6 (1C, C-5), 136.2 (1C. C-1tolyl), 137.6 (1C, C-1phenyl), 138.3 (1C, C-4tolyl), 138.6 
(1C, C-4phenyl), 143.1 (1C, C-7), 165.0 (1C, CONH), 168.4 (1C, C-1). IR (neat): ν [cm-1] = 2937 (C-
Haliph.), 1728 (C=Oamide), 1600 (C=C). HPLC (method 1): tR = 23.08 min, purity 97.1%. 
 
Separation of regioisomeric 26a and 26b: As described above, a mixture of the regioisomers 24a and 
24b (74 mg, 0.2 mmol) was reacted with 5 M NaOH (5 mL) and the resulting mixture of acids 25a and 
25b was subsequently coupled with primary amine 13 (51 mg, 0.2 mmol) and HATU (83 mg, 0.22 
mmol). Pale yellow oil, yield 51 mg (46%). The 1:1-mixture of regioisomers 26a and 26b was separated 
by preparative HPLC (method 2, acetonitrile : H2O = 70:30, 60 min per run). 26a: Colorless solid, yield 




4.3.13. Methyl 2-isobutyl-8-nitro-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxylate (27a) and  
Methyl 2-isobutyl-6-nitro-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxylate (27c) 
Concentrated H2SO4 (1.04 mL) was added slowly, with ice-water cooling and stirring, to 100% HNO3 
(1.04 mL). 11 (280 mg, 1.02 mmol, 1 equiv.) was dissolved in nitromethane (0.5 mL) and cooled to 
0 °C. After nitrating acid was added slowly at this temperature, the solution was warmed to rt and stirred 
for 2 h. Then ice-water was poured into the reaction mixture, neutralized with 3 M NaOH (10 mL) and 
extracted with CH2Cl2 (2 x 15 mL) and ethyl acetate (2 x 15 mL). The combined organic layers were 
dried (Na2SO4) and concentrated in vacuo. The residue was purified by fc (Ø = 3 cm, h = 17 cm, 
cyclohexane / ethyl acetate = 7 : 2, V = 20 mL, Rf = 0.02 (cyclohexane / ethyl acetate = 7 : 2)) to give a 
mixture of regioisomers 27a and 27c. Pale yellow oil, yield 273 mg (83%). C16H18N2O5, 
Mr = 318.3. Ratio of 27a:27c = 7:3. Exact mass (ESI): m/z = 341.1109 (calcd. 341.1108 for 
C16H18N2NaO5 [MNa+]). IR (neat): ν [cm-1] = 2959 (C-Halkyl), 1713 (C=O), 1636 (NC=O), 1524 (N=O), 
1346 (NO2 arom.). HPLC (method 1): tR = 20.43 min, purity 97.7%. The two regioisomers were separated 
by fc (Ø = 2.5 cm, h = 24 cm, CH2Cl2 : ethyl acetate = 95 : 5, V = 20 mL) to give 27a and 27c.  
27a (Rf = 0.38, CH2Cl2 : ethyl acetate = 95 : 5): Pale yellow solid, mp 109 °C, yield 178 mg (54%). 
C16H18N2O5, Mr = 318.3. Exact mass (ESI): m/z = 341.1106 (calcd. 341.1108 for C16H18N2NaO5 
[MNa+]). 1H NMR (CDCl3): δ [ppm] = 0.94 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 2.14 – 2.21 (m, 1H, 
NCH2CH(CH3)2), 3.45 (d, J = 7.6 Hz, 2H, NCH2CH(CH3)2), 3.91 (s, 3H, CO2CH3), 4.02 (s, 2H, 3-CH2), 
7.53 (d, J = 8.5 Hz, 1H, 6-CH), 7.84 (s, 1H, 5-CH), 8.30 (dd, J = 8.5/2.4 Hz, 1H, 7-CH), 8.92 (d, J = 2.0 
Hz, 1H, 9-CH). 13C NMR (CDCl3): δ [ppm] = 20.1 (2C, NCH2CH(CH3)2), 27.7 (1C, NCH2CH(CH3)2), 
44.2 (1C, C-3), 53.0 (1C, CO2CH3), 56.6 (1C, NCH2CH(CH3)2), 124.8 (1C, C-7), 127.3 (1C, C-9), 130.9 
(1C, C-6), 136.0 (1C, C-4), 138.2 (1C, C-9a), 138.4 (1C, C-5a), 139.2 (1C, C-5), 148.3 (1C, C-8), 165.4 
(1C, CO2CH3), 166.2 (1C, C-1). FT-IR (neat): ν [cm-1] = 2963 (C-Halkyl), 1709 (C=O), 1632 (NC=O), 
1520 (N=O), 1354 (NO2 arom.). HPLC (method 1): tR = 20.81 min, purity 96.5%.  
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27c (Rf = 0.24, CH2Cl2 : ethyl acetate = 95 : 5): Pale yellow oil, yield 29 mg (9%). C16H18N2O5, 
Mr = 318.3. Exact mass (ESI): m/z = 341.1116 (calcd. 341.1108 for C16H18N2NaO5 [MNa+]). 1H NMR 
(CDCl3): δ [ppm] = 0.94 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 2.02 – 2.12 (m, 1H, NCH2CH(CH3)2), 
3.44 (d, J = 6.2 Hz, 2H, NCH2CH(CH3)2), 3.89 (s, 3H, CO2CH3), 4.00 (s, 2H, 3-CH2), 7.63 (t, J = 
8.0 Hz, 1H, 8-CH), 7.96 (s, 1H, 5-CH), 8.10 (dd, J = 8.1/1.4 Hz, 1H, 7-CH), 8.31 (dd, J = 7.9/1.3 Hz, 
1H, 9-CH). 13C NMR (CDCl3): δ [ppm] = 20.1 (2C, NCH2CH(CH3)2), 27.6 (1C, NCH2CH(CH3)2), 43.8 
(1C, C-3), 53.0 (1C, CO2CH3), 56.2 (1C, NCH2CH(CH3)2), 126.7 (1C, C-7), 127.2 (1C, C-5a), 129.9 
(1C, C-8), 134.6 (1C, C-4), 134.9 (1C, C-5), 136.2 (1C, C-9), 139.2 (1C, C-9a), 148.3 (1C, C-6), 165.6 
(1C, CO2CH3), 166.3 (1C, C-1). IR (neat): ν [cm-1] = 2959 (C-Halkyl), 1712 (C=O), 1636 (NC=O), 1528 
(N=O), 1343 (NO2 arom.). HPLC (method 1): tR = 20.81 min, purity 92.9%. 
 
4.3.14. 2-Isobutyl-N-{4-[N-methyl-N-(tetrahydro-2H-pyran-4-yl)aminomethyl]phenyl}-8-nitro-1-
oxo-2,3-dihydro-1H-2-benzazepine-4-carboxamide (29a) and 
2-Isobutyl-N-{4-[N-methyl-N-(tetrahydro-2H-pyran-4-yl)aminomethyl]phenyl}-6-nitro-1-oxo-2,3-
dihydro-1H-2-benzazepine-4-carboxamide (29c) 
Amine 13 (193 mg, 0.66 mmol, 1 equiv.) was added to a vigorously stirred mixture of the regioisomeric 
acids 28a and 28c (200 mg, 0.66 mmol, 1 equiv.), NEt3 (182 µL, 133 mg, 1.32 mmol, 2 equiv.) and 
HATU (275 mg, 0.72 mmol, 1.1 equiv.) in abs. THF (8 mL). The mixture was stirred overnight at rt. 
After further addition of NEt3 (133 mg, 1.32 mmol, 2 equiv.) and HATU (274.9 mg, 0.72 mmol, 
1.1 equiv.) the mixture was stirred for 3 h. The solvent was removed in vacuo and saturated NaHCO3-
solution (25 mL) was added to the residue. The mixture was extracted with ethyl acetate (3 x 30 mL). 
The combined organic layers were dried (Na2SO4) and concentrated in vacuo to give the amides 29a and 
29c as a light brown oil as mixture of regioisomers. This was purified and separated by fc (Ø = 2.5 cm, 
h = 17 cm, CH2Cl2 : H3COH = 96 : 4 + 1% NH3, V = 20 mL) to give the pure amides 29a and 29c, and a 
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fraction containing a mixture, which was further separated by another fc (Ø = 1 cm, h = 17 cm, CH2Cl2 : 
H3COH = 97 : 3 + 1% NH3, V = 5 mL).  
29a (Rf = 0.28, CH2Cl2 : H3COH = 95 : 5 + 1% NH3). Yellow solid, mp 200 °C, yield 32 mg (9%). 
C28H34N4O5, Mr = 506.6.  Exact mass (ESI): m/z = 507.2595 (calcd. 507.2602 for C28H35N4O5 [MH+]). 
1H NMR (CDCl3): δ [ppm] = 0.89 (d, J = 6.6 Hz, 6H, NCH2CH(CH3)2), 1.67 – 1.84 (m, 4H, 3-CHpyran, 
5-CHpyran), 1.98 – 2.06 (m, 1H, NCH2CH(CH3)2), 2.29 (s, 3H, CH3), 2.81 – 2.88 (m, 1H, 4-CHpyran), 
3.31 – 3.36 (m, 2H, 2-CHpyran, 6-CHpyran), 3.40 (d, J = 7.6 Hz, 2H, NCH2CH(CH3)2), 3.72 (s, 2H, CH2N), 
3.99 (s, 2H, 3-CH2), 4.02 – 4.06 (m, 2H, 2-CHpyran, 6-CHpyran), 7.28 (d, J = 8.5 Hz, 1H, 6-CH), 7.36 (d, 
J = 8.4 Hz, 2H, 3-CHaniline, 5-CHaniline), 7.38 (s, 1H, 5-CH), 7.68 (d, J = 8.4 Hz, 2H, 2-CHaniline, 6-
CHaniline), 8.18 (dd, J = 8.5/2.4 Hz, 1H, 7-CH), 8.86 (d, J = 2.4 Hz, 1H, 9-CH), 9.01 (s, 1H, NH). 13C 
NMR (CDCl3): δ [ppm] = 20.1 (2C, NCH2CH(CH3)2), 27.7 (1C, NCH2CH(CH3)2), 28.6 (2C, C-3pyran, C-
5pyran), 36.8 (1C, CH3), 44.5 (1C, C-3), 56.4 (1C, NCH2CH(CH3)2), 56.9 (1C, CH2N), 59.5 (1C, C-4pyran), 
67.5 (2C, C-2pyran, C-6pyran), 120.4 (2C, C-2aniline, C-6aniline), 124.8 (1C, C-7), 126.8 (1C, C-9), 130.3 (2C, 
3-Caniline, 5-Caniline), 130.4 (1C, C-6), 132.8 (1C, C-5), 133.6 (1C, C-4aniline), 137.4 (1C, C-1aniline), 137.5 
(1C, C-9a), 138.6 (1C, C-5a), 140.8 (1C, C-4), 147.8 (1C, C-8), 164.0 (1C, CONH), 166.5 (1C, C-1). IR 
(neat): ν [cm-1] = 3267 (N-H), 2920 (C-Halkyl), 1632 (C=O), 1520 (N=O), 1343 (NO2 arom.). HPLC 
(method 1): tR = 17.43 min, purity 97.3%.  
29c (Rf = 0.32, CH2Cl2 : H3COH = 95 : 5 + 1% NH3). Pale yellow solid, mp 197 °C, yield 45.6 mg 
(14%). C28H34N4O5, Mr = 506.6.  Exact mass (ESI): m/z = 507.2595 (calcd. 507.2602 for C28H35N4O5 
[MH+]). 1H NMR (CDCl3): δ [ppm] = 0.87 (d, J = 6.6 Hz, 6H, NCH2CH(CH3)2), 1.64 – 1.79 (m, 4H, 3-
CHpyran, 5-CHpyran), 1.94 – 2.05 (m, 1H, NCH2CH(CH3)2), 2.22 (s, 3H, CH3), 2.62 – 2.70 (m, 1H, 
4-CHpyran), 3.33 – 3.40 (m, 4H, NCH2CH(CH3)2, 2-CHpyran, 6-CHpyran), 3.60 (s, 2H, CH2N), 3.89 – 4.06 
(m, 4H, 3-CH2, 2-CHpyran, 6-CHpyran), 7.33 (d, J = 8.4 Hz, 2H, 3-CHaniline, 5-CHaniline), 7.40 (s, 1H, 5-CH), 
7.56 (t, J = 8.0 Hz, 1H, 8-CH), 7.69 (d, J = 8.5 Hz, 2H, 2-CHaniline, 6-CHaniline), 8.04 (dd, J = 8.1/1.4 Hz, 
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1H, 7-CH), 8.25 (dd, J = 7.9/1.3 Hz, 1H, 9-CH). A signal for the NH proton is not seen in the spectrum. 
13C NMR (CDCl3): δ [ppm] = 19.9 (2C, NCH2CH(CH3)2), 27.5 (1C, NCH2CH(CH3)2), 29.1 (2C, C-
3pyran, C-5pyran), 37.5 (1C, CH3), 44.0 (1C, C-3), 55.9 (1C, NCH2CH(CH3)2), 57.3 (CH2N), 59.5 (C-
4pyran), 67.6 (2C, C-2pyran, C-6pyran), 120.2 (2C, C-2aniline, C-6aniline), 126.9 (1C, C-7), 127.3 (1C, C-5a), 
128.2 (1C, C-5), 129.4 (2C, C-3aniline, C-5aniline), 129.5 (1C, C-8), 135.8 (1C, C-9), 136.1 (1C, C-1aniline), 
136.8 (1C, C-4aniline), 138.5 (1C, C-9a), 139.3 (1C, C-4), 147.2 (1C, C-6), 164.0 (1C, CONH), 166.3 (1C, 
C-1). IR (neat): ν [cm-1] = 3291 (N-H), 2955 (C-Halkyl), 1628 (C=O), 1524 (N=O), 1343 (NO2arom.). 
HPLC (method 1): tR = 17.13 min, purity 98.4%. 
 
4.4. Biological evaluation 
4.4.1. Affinity towards CCR2 receptors  
Chemicals and reagents 
[3H]INCB3344 (32 Ci/mmol) was purchased from ViTrax (Placentia, USA - custom synthesis). BMS22 
was purchased from Tocris Bioscience (Bristol, UK) 
Cell culture and membrane preparation 
U2OS cells stably expressing the human CCR2 receptor (Invitrogen, Carlsbad, CA) were cultured in 
McCoys5a medium supplemented with 10% fetal calf serum, 2 mM glutamine, 0.1 mM non-essential 
amino acids (NEAAs), 25 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 1 mM 
sodium pyruvate, 100 IU/mL penicillin, 100 μg/mL streptomycin, 100 μg/mL G418, 50 μg/mL 
hygromycin, and 125 μg/mL zeocin in a humidified atmosphere at 37 °C and 5% CO2. Cell culture and 
membrane preparation were performed as described previously.18  
[3H]INCB3344 binding assays 
Binding assays were performed in a 100 µL reaction volume containing 50 mM Tris-HCl buffer (pH 
7.4), 5 mM MgCl2, 0.1% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonic acid (CHAPS) 
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and 20 µg of membrane protein at 25 °C. Nonspecific binding was determined with 10 µM BMS22. 
Displacement assays were performed with 7 nM [3H]INCB3344 using at least 6 concentrations of 
competing ligand for 120 minutes of incubation. The HP D300 digital dispenser from Tecan 
(Männedorf, Switzerland) was used to dispense the compounds in DMSO directly into the assay 
plate. Incubations were terminated by dilution with ice-cold 50 mM Tris-HCl buffer supplemented with 
0.05% CHAPS. Separation of bound from free radioligand was performed by rapid filtration through a 
96-well GF/B filter plate using a PerkinElmer Filtermate-harvester (PerkinElmer, Groningen, The 
Netherlands). Filters were washed 10 times with ice-cold wash buffer, and 25 µL of Microscint 
scintillation cocktail (PerkinElmer) was added to each well; the filter-bound radioactivity was 
determined by scintillation spectrometry using the P-E 1450 Microbeta Wallac Trilux scintillation 
counter (PerkinElmer). 
Data analysis 
All experiments were analysed using the nonlinear regression curve fitting program Prism 5 (GraphPad, 
San Diego, CA).  
 
4.4.2. Ca2+ flux assay at CCR2 receptors  
Cell culture 
Chem-1 cell line transfected with human CCR2 (ChemiSCREEN™ CCR2B Calcium-Optimized FLIPR 
Cell Line, Merck Millipore) was used for the intracellular calcium flux assay. U2OS β-arrestin cell line 
transfected with murine CCR2 (93-0543C3, DiscoveRx Corporation, Ltd.) was used for the β-arrestin 
recruitment assay.   
Measurement of intracellular calcium flux (Gq signaling pathway) 
Chem-1 cells transfected with human CCR2 were cultured in DMEM high glucose medium 
(supplemented by 10% FCS, 1 mM pyruvate, 15 mM HEPES, 500 µg/mL geniticine and non-essential 
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amino acids (NEAA)). The cells were transferred into Optimem (supplemented by 5% FCS, 50 U/mL 
penicillin and 50 µg/mL streptomycine and NEAA) and seeded into 384-well plates (µCLEAR/black 
Greiner Bio One) at a density of 5000 cells/25 µL. Cells were incubated for approximately 24 h at 37 
°C, 5% CO2. Before the assay medium was removed and the cells were incubated with Fluo-4 solution 
(25 µL Tyrode´s solution containing 3 µM Fluo-4 AM (1 mM DMSO stock solution), 0.4 mg/mL 
brilliant black, 2.5 mM probenicide, 0.03% pluronic F-127) for 60 min at 37 °C, 5% CO2. The 
compounds were dissolved in DMSO with 10 mM stock concentration followed by further dilution with 
DMSO in 1/3.16 steps. Required test solutions for the assay were obtained by dilution with Tyrode´s 
solution containing 2 mM CaCl2 and 0.05% BSA. Compounds (10 μL per well) were added and cells 
were incubated for 10 min at 37 °C, 5% CO2. Then 20 µL of agonist solution (recombinant human 
CCL2 (PeproTech, 300-04) in Tyrode´s solution with 0.05% BSA) were added. CCL2 was applied at 
EC50, which was determined in an experiment prior to compound testing (approximately 5 nM). 
Fluorescence intensity (excitation: 485 nm, emission: 520 nm) was measured for 120 s in 1.0 s intervals 
by a proprietary fluorescence measuring device. IC50 values were fitted using a 4 parameter logistic 
function (Hill function). 
 
4.4.3. Affinity toward the CCR5 
Chemicals and reagents 
[3H]TAK-779 (79.1 Ci/mmol) was purchased from PerkinElmer (custom synthesis). 
Cell culture and membrane preparation and [3H]TAK-779 binding assay 
The CCR5 receptor containing membrane fragments were used according to the instructions of the 
manufacturer and incubated with various concentrations of the test compound, 2 nM [3H]TAK-779 and 
binding buffer (50 mM HEPES pH 7.4, 5 mM MgCl2, 1 mM CaCl2 and 0.2% BSA) at room 
temperature. The filter mats were washed with a buffer solution (50 mM HEPES pH = 7.4, 500 mM 
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NaCl-solution and 0.1% BSA). The test compound solutions were prepared by dissolving approximately 
10 µmol (usually 2-4 mg) of the test compound in DMSO so that a 10 mM stock solution was obtained. 
To obtain the required test solutions for the assay, the DMSO stock solution was diluted with the 
respective assay buffer. The filter mats were presoaked in 0.5% aqueous polyethylenimine solution for 2 
h at room temperature before use. All binding experiments were carried out in duplicates in 96-well 
multiplates. The concentrations given are the final concentrations in the assay. Generally, the assays 
were performed by addition of 50 µL of the respective assay buffer, 50 µL test compound solution in 
various concentrations (10-5, 10-6, 10-7, 10-8, 10-9 and 10-10 mol/L), 50 µL of corresponding radioligand 
solution and 50 µL of the respective receptor preparation into each well of the multiplate (total volume 
200 µL). The receptor preparation was always added last. During the incubation, the multiplates were 
shaken at a speed of 500-600 rpm at the specified temperature. The assays were terminated after 120 
min by rapid filtration using the harvester. During the filtration, each well was washed five times with 
300 µL of water. Subsequently, the filter mats were dried at 95 °C. The solid scintillator was melted on 
the dried filter mats at a temperature of 95 °C for 5 min. After solidifying of the scintillator at room 
temperature, the trapped radioactivity in the filter mats was measured with the scintillation analyser. 
Each position on the filter mat corresponding to one well of the multiplate was measured for 5 min with 
the [3H]-counting protocol. The overall counting efficiency was 20%.  
Data analysis 
All experiments were analysed using the nonlinear regression curve fitting program Prism 3 (GraphPad, 
San Diego, CA).  
 
4.4.4. BRET-based cAMP assay at the CCR5 receptor 
Cell culture 
The human embryonic kidney (HEK293 T) were cultured in 10 cm cell culture plates in DMEM/F-12 
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medium, supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1% penicillin- 
streptomycin and incubated at 37°C in a humid atmosphere with 5% CO2. 
cAMP BRET assay 
HEK293T cells were transiently transfected with 1µg of the human receptor CCR5 and 2µg of the 
biosensor CAMYEL, using the TransIT-293 transfection reagent from Mirus 293 (Mirus Bio LLC, 
Madison, USA). 24 hours after transfection, the cells were seeded in a half-area white 96-wells plate 
(Grainer-Bio One) containing 20.000 cells/well in 100 µL of complete DMEM/F-12 phenol red-free 
medium. After incubation at 37°C in a humid atmosphere with 5% CO2 overnight, the medium was 
removed and 30 µL of dPBS supplemented with CaCl2 and MgCl2 (Gibco, Life Technologies) were 
added to each well. After additional hour of incubation at 37°C the substrate coelenterazine h (Promega, 
Madison, USA) was added in each well to a final concentration of 5 µM and incubated for 5 min in 
darkness. Various concentrations of test compounds (prepared in dPBS, pH 7.4, containing 0.2% BSA, 
1% DMSO, 10 µM forskoline, and 0.2 nM of the chemokine CCL4 or 1 nM of the chemokine CCL5) 
were added to a final volume of 50 µL per well and incubated for additional 10 min at room 
temperature. Bioluminescence was measured with a microplate reader Clariostar (BMG labtech, 
Ortenberg, Germany). Each concentration was measured in triplicate. 
 
Data analysis 
To characterize the allosteric profile of novel ligands, we applied the ternary complex model of 
allosterism to analyze the data obtained from the functional assays. The assumptions were that the 
allosteric modulators do not cause the depression of maximal response or the suppression of the basal 
activity. The depression of maximal response or the suppression of the basal activity are not accounted 
for in an ATCM model. Importantly, even if these assumptions do not hold entirely true for all the novel 
allosteric modulators, this analysis enables a first approximation and a semi-empirical estimate of 
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cooperativity.19,20 The data from functional studies, where discrete concentrations of agonist CCL4 was 
used, were fitted to following equations using Prism 7.0: 
   (1) 
    (2) 
Where Kapp described the occupancy of the orthosteric site, KA was the EC50 value of CCL4 or CCL5 for 
the investigated receptor, [c] the concentration of CCL4 or CCL5 used, [B] the concentration of novel 
allosteric modulator, KB the equilibrium dissociation constant of modulator binding, and αβ the ternary 
complex constant, which denotes cooperativity factor.21 In the cAMP assay the KA value for CCL4 was 
set to 0.2 nM. The concentration of the chemokine CCL5 was set to 1 nM.    
 
4.5 Molecular modelling 
All molecular modelling studies were carried out on an Intel CoreTM i7 processor, 8 GB memory with 
Windows 10 operating system using MOE (Molecular Operating Environment, 2016.08; Chemical 
Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2012.) 
as the computational software.  
For the calculations performed using AM1 of the MOE software package (Molecular Operating 
Environment (MOE), 2012.10; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, 
Montreal, QC, Canada, H3A 2R7, 2012) the 3D-structures were drawn using Module Builder. The 
stochastic conformational search was performed under standard conditions. (Method: Stochastic, 
Rejection Limit 100, Iteration Limit 10000, RMS gradient: 0.005, MM iteration limit 500, RMSD limit: 
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Captions of all Figures, Schemes and Tables 
Figure 1: Design of 2-benzazepin-1-ones 3 derived from TAK-779 (1) and TAK-652 (2). 
 
Figure 2: I) Alignment of central core structures of TAK-779 (A, blue) with 7-p-tolyl derivative 26b (B, 
pink). II) Alignment of central core structures of TAK-652 (C, orange) with 7-p-tolyl derivative 26b (B, 
pink). 
 
Figure 3: The BRET-based cAMP assay for compounds 14 and TAK-779 (1) with CCL4 at the CCR5 
receptor.  
 
Scheme 1: Synthesis of compounds 14 and 16. Reagents and reaction conditions: (a) 1. NaOCH3, 
H3COH, rt, 2 h; 2. HCl/Et2O, 89%. (b) Monomethyl phthalate (7), SOCl2, pyridine; then addition of 
6·HCl, pyridine, CH2Cl2, rt, 4 h, 64%. (c) NaH, THF, reflux, 3 h, 58%. (d) NaBH4, H3COH, 0 °C, 1 h, 
58%. (e) H3CSO2Cl, NEt3, DBU, CH2Cl2, rt, 12 h, 76%. (f) 5 M NaOH, H3COH, reflux, 40 min, 100%. 
(g) NEt3 (2 equiv.), HATU (1.1 equiv.), THF, rt, 12 h, 14: 48%, 16: 8%. 
 
Scheme 2: Synthesis of 7- and 8-(p-tolyl)-2-benzazepine-4-carboxamides 26a,b. Reagents and reaction 
conditions: (a) Br2, NaOH, H2O, reflux, 72 h, 95%. (b) TMSCl, H3COH, rt, 12 h, 94%. (c) 1. SOCl2, 
pyridine; 2. 6·HCl, pyridine, CH2Cl2, rt, 4 h, 64%. (d) NaH, THF, reflux, 3 h, 21a: 36%, 21b: 38%. (e) 
NaBH4, H3COH, 0 °C, 1 h, 22a: 58%, 22b: 45%. (f) H3CSO2Cl, NEt3, DBU, CH2Cl2, rt, 12 h, 23a: 74%, 
23b: 84%. (g) 4-Methylbenzeneboronic acid, PdCl2(dppf) (5 mol%), KOAc, DME, reflux, 12 h, 24a: 
50%, 24b: 58%. (h) 5 M NaOH, H3COH, reflux, 30 min, 97%. (i) 13, HATU, NEt3, THF, rt, 12 h, 26a: 




Scheme 3: Synthesis of NO2 derivatives 29 and acetamide 34a. Reagents and reaction conditions: 
(a) HNO3 (100%), H2SO4 (95 – 97%), CH3NO2, rt, 2 h, 83%. (b) 5M NaOH, H3COH, reflux, 97%.  (c) 
13, HATU, NEt3, THF, rt, 12 h, 29a: 9%, 29c: 14%. (d) Fe, conc. HCl, EtOH, reflux, 2 h, 75%. (e) 
Ac2O, NEt3, CH2Cl2, 6 h, rt, 59%. (f) NaOH, H3COH, 10 min, rt. (g) Ac2O, NEt3, CH2Cl2, 6 h, rt, 69%. 
(h) 13, HATU, NEt3, THF, rt, 12 h, 47%. 
 
Scheme 4: Synthesis of sulfonamide 38a: Reagents and reaction conditions: (a) Fe, conc. HCl, EtOH, 
reflux, 2 h, 74%. (b) CH3SO2Cl (1 equiv.), NEt3, CH2Cl2, 3 d, then 4 x 0.3 equiv. CH3SO2Cl and NEt3 
every 6 h, rt, 91%. (c) NaOH, H3COH, 20 min, rt, 43%. (d) LiOH (4 equiv.), H3COH, 3 h rt, 1 h 50 °C, 
53%.  (e) 13, HATU, NEt3, THF, rt, 12 h, 20%. 
 
Table 1: Receptor affinities and activities at CCR2 and CCR5 receptors. 
Under the Table 
[%] inhibition at a test compound concentration of 1 μM (n = 3). n.d. not determined. 
[a] Displacement of the radioligand [3H]INCB3344 at a concentration of 1 µM of the test 
compound (n = 3). 
[b]  Inhibition of Ca2+ mobilization after activation by 5 nM MCP-1 (n = 3). 
 [c] Displacement of the radioligand [3H]TAK-779 at a concentration of 1 µM of the test 
compound (n = 3). 
[d] Stimulation of cAMP production after inhibition with 0.2 nM CCL4 (n = 3). 
 
 
